PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PI3K (Phosphoinositide 3-kinases)

PIK3CA mutation • PTEN deletion

fulvestrant • Aliqopa (copanlisib)

BORXPTEN: Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion (clinicaltrials.gov)

P2, N=22, Recruiting, University of Utah | Trial primary completion date: Dec 2025 --> Dec 2026

7 days ago

Trial primary completion date

PTEN (Phosphatase and tensin homolog)

PTEN deletion

bortezomib

Clinicopathological Diagnosis and Prognosis of Endometrioid Borderline Ovarian Tumors: Dual Case Reports and Literature Review. (PubMed, Cancer Rep (Hoboken))

EBOT are infrequent and may coexist with endometriosis or endometrioid carcinoma. Our cases demonstrated a heterozygous deletion of the CTNNB1 gene in one case, while a heterozygous deletion of the PTEN gene in the other. Surgery remains the main treatment, reflecting its efficacy in achieving disease control and a favorable prognosis.

1 month ago

Review • Journal

ER (Estrogen receptor) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • WT1 (WT1 Transcription Factor)

PTEN deletion

2ms

PROGECT: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry (clinicaltrials.gov)

P=N/A, N=1500, Recruiting, University of Kansas Medical Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026

2 months ago

Trial completion date • Trial primary completion date

BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • BRCA (Breast cancer early onset)

TP53 mutation • PTEN deletion • PTEN mutation • PALB2 mutation • BRCA mutation

3ms

PRC2/FOXO1-Mediated Repression Determines Interchangeability of ETS Oncogenes in Prostate Cancer and Ewing Sarcoma. (PubMed, Mol Cancer Res)

AKT-mediated degradation of FOXO1 and subsequent loss of the ERG/PRC2 interaction provides a mechanism for ERG synergy with PTEN deletion in prostate cancer. Implications: These findings indicate that ETS transcription factors that drive prostate cancer and Ewing sarcoma utilize similar mechanisms and thus could be targeted by similar therapeutic approaches.

3 months ago

Journal

PTEN (Phosphatase and tensin homolog) • EWSR1 (EWS RNA Binding Protein 1) • ERG (ETS Transcription Factor ERG) • ETV1 (ETS Variant Transcription Factor 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • ETV5 (ETS Variant Transcription Factor 5) • ETV4 (ETS Variant Transcription Factor 4)

PTEN deletion

3ms

Prognostic Significance of PTEN Loss in Prostate Cancer: A Meta-Analysis of Gleason Grade and Clinical Outcomes. (PubMed, Cancers (Basel))

PTEN loss correlates with higher GG and poorer clinical outcomes in PCa. Incorporating PTEN assessment into clinical decision making could improve risk stratification, guiding early intervention strategies and identifying patients suitable for active surveillance.

3 months ago

Clinical data • Retrospective data • Review • Journal

PTEN (Phosphatase and tensin homolog)

PTEN deletion

4ms

Comparative analysis of S100A10 and S100A11 in MASLD and hepatic cancer development revealed a tumor suppressive role for S100A10. (PubMed, Cell Death Dis)

The results show that both S100A10 and S100A11 play active roles in the development of MASLD. However, these two closely associated proteins present opposite contributions to hepatic cancer, S100A10 being protective and S100A11 deleterious.

4 months ago

Clinical • Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog)

PTEN deletion

4ms

A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis. (PubMed, Front Immunol)

Our findings provide clues for prognosis evaluation in BM patients. They also establish a theoretical basis for predicting immunotherapy efficacy.

4 months ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • PTPRT (Protein tyrosine phosphatase receptor type T) • DUSP4 (Dual Specificity Phosphatase 4)

PTEN deletion • PTEN mutation

5ms

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations (clinicaltrials.gov)

P2, N=7, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2026 --> Aug 2025

5 months ago

Trial completion date

PIK3CA mutation • PTEN deletion

fulvestrant • Aliqopa (copanlisib)

5ms

Novel murine cell lines with defined mutations model different histological subtypes of epithelial ovarian cancer. (PubMed, Dis Model Mech)

RNAseq data from 16 cell lines reveal the gene expression profile across distinct models with different histotypes. This versatile collection of murine cell lines supports translationally relevant studies in ovarian cancer.

5 months ago

Preclinical • Journal

KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog)

KRAS G12D • PTEN deletion • KRAS G12

5ms

Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation. (PubMed, Nat Cancer)

This BC reprogramming was associated with the activation of innate immunity. Pharmacological targeting of interleukin-1, JAK-STAT and NF-κB as well as genetic deletion of Nfkb inhibit Pten-induced cell plasticity and reprogramming in a cellular autonomous manner, opening new opportunities for prevention and treatment of prostate cancer.

5 months ago

Journal

PTEN (Phosphatase and tensin homolog)

PTEN deletion

6ms

Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growth. (PubMed, bioRxiv)

EGFR/PI3K inhibitor combination causes apoptosis and reduction in tumor growth in cells with EGFR amplification and PI3K alteration. Dual inhibition of EGFR/PI3K presents as a potential targeted therapy in patients with EGFR amplification and aberrant PI3K signaling.

6 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)

EGFR mutation • PIK3CA mutation • EGFR amplification • PTEN deletion • PTEN mutation